Literature DB >> 26711791

The EORTC QLQ-CR29 quality of life questionnaire for colorectal cancer: validation of the Dutch version.

A M Stiggelbout1, M Kunneman2, M C M Baas-Thijssen2, P A Neijenhuis3, A K Loor4, S Jägers5, R Vree6, C A M Marijnen7, A H Pieterse2.   

Abstract

PURPOSE: To validate the Dutch version of the EORTC QLQ-CR29 quality of life questionnaire for colorectal cancer.
METHODS: We translated and pilot-tested the original questionnaire in the Netherlands, following EORTC guidelines. We assessed factor structure, reliability and construct validity in different samples of patients from four hospitals.
RESULTS: Of 296 patients, 236 (80 %) returned the questionnaire, and 27 out of 48 patients returned the retest questionnaire. In addition to the original three scales, we found a reliable bowel functioning scale (α = 0.80), reducing the number of individual items by five. Two of the other scales had sufficient to good reliability (urinary frequency, α = 0.71, original α = 0.75, body image α = 0.80, original α = 0.84), the third, blood and mucus in stool, only moderate (α = 0.56, original α = 0.69). Item functioning was sufficient to excellent for all but two items (urinary incontinence and dysuria). Construct validity was similar to that in earlier studies.
CONCLUSION: We found a very satisfactory scale for bowel problems, in patients both with and without stoma. The body image and urinary incontinence scales were reliable, and construct validity was sufficient. We suggest the questionnaire to be adapted to decrease the number of individual items, improve the scales, and therefore increase reliability of the entire questionnaire.

Entities:  

Keywords:  Colorectal cancer; Health-related quality of life; QLQ-CR29; Validation

Mesh:

Year:  2015        PMID: 26711791      PMCID: PMC4893365          DOI: 10.1007/s11136-015-1210-5

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


Introduction

Colorectal cancer is a prevalent cancer, and both the disease and its treatment strongly impact quality of life (QoL). To allow for the evaluation of new treatments, the European Organisation for Research and Treatment of Cancer (EORTC) developed the colorectal QoL module QLQ-CR38 [1] as an adjunct to the generic EORTC QLQ-C30. Later, this was revised to the shorter QLQ-CR29 [2] and validated in an international study [3]. The resulting QLQ-CR29 consisted of four scales and 19 individual items. Later validation studies were reported for the Polish [4] and Spanish [5] versions. Validation of the Danish QLQ-CR38 [6] suggested the QLQ-CR29 to be more valid than the QLQ-CR38. In the Spanish QLQ-CR29, the blood and mucus scale was not confirmed; in the Polish only the body image scale was reliable, and the urinary incontinence scale approached acceptable reliability. Construct validity was limited for the Polish version and showed ambiguous results for the Spanish. In both cases, the authors nevertheless concluded the questionnaire to be reliable and valid. These equivocal results led us to assess the reliability and validity of the Dutch version and to assess whether additional scales might result in a reduction in the number of individual items.

Materials and methods

Translation and procedures

The QLQ-CR29 had been translated into Flemish/Dutch by the EORTC Quality of Life Group, following their Translation Procedure Manual Instructions [7]. Differences in the Dutch language exist between Belgium and the Netherlands, and pilot testing was undertaken to reword some items for a Dutch population, in 29 patients with colorectal cancer from the Leiden University Medical Center (LUMC). Suggested changes were discussed with experts of the EORTC, resulting in a final Dutch translation. Consecutive patients were recruited from two academic and two peripheral hospitals in the western region of the Netherlands [LUMC—Departments of Surgery and Radiotherapy, Alrijne Hospital Leiden (former locations Diaconessen Hospital and Rijnland Hospital)], and Erasmus Medical Center Rotterdam, between May 2011 and December 2012. In three departments (Diaconessen Hospital, LUMC—Surgery, and ErasmusMC), research nurses handed the questionnaire to the patients (n = 123, response rate 79 %) at the time of their follow-up visit, and in one hospital (Rijnland), the questionnaire was sent to patients (n = 80, response rate 83 %) who had undergone treatment for colorectal cancer between May and December 2011. In one department (LUMC—Radiotherapy), the questionnaire was sent to patients (n = 93, response rate = 78 %) who participated in other studies [8, 9]. Of the 296 patients receiving a questionnaire, 244 returned it, and we included 236 completed questionnaires (response 80 %). Time between surgery and filling out the questionnaire ranged from 5 months to 12 years. No information is available on the non-responders, unfortunately, but given the nature of the task, filling out a short questionnaire, we do not expect major non-response bias. For convergent validity, participants were additionally asked to fill out the EORTC QLQ-C30. For test–retest reliability, we approached patients who had indicated their willingness in the first questionnaire. The questionnaire was sent to every fifth participant within 2 weeks of returning the first questionnaire. Twenty-seven patients (out of 48 invited, 56 %) filled in the questionnaire twice, on average 19 days after the first (range 4–46 days). Patient characteristics are presented in Table 1.
Table 1

Patient characteristics

PatientsMain sample N = 236Retest sample N = 27
Age
 Mean age, years ± SD (range)65 ± 11.3 (24–90)64 ± 14.1 (24–83)
 ≤65 years114 (48 %)13 (48 %)
Male143 (61 %)20 (74 %)
Marital statusa
 Single34 (15 %)8 (30 %)
 Married172 (75 %)18 (67 %)
 Widow(er)24 (10 %)1 (4 %)
Educational levela
 Low74 (32 %)7 (28 %)
 Intermediate91 (40 %)11 (44 %)
 High64 (28 %)7 (28 %)
Stoma, yesb 68 (29 %)12 (44 %)
Curative treatment196 (83 %)23 (82 %)

aDoes not count up to 236 due to missing data

bAt the time of filling in the questionnaire

Patient characteristics aDoes not count up to 236 due to missing data bAt the time of filling in the questionnaire

Statistical analysis

We assessed item performance, by proportion of floor and ceiling effects, and by test–retest reliability (intraclass correlation coefficients, ICCs). Since the QLQ-CR29 was shown to consist only of few and mostly two-item scales, we carried out a principal component analysis to detect potential additional subscales, based on eigenvalues (>1.0). Items 49–54 on bowel problems (patients without a stoma) and stoma problems (patients with a stoma), respectively, were used as if the same items for patients without and with a stoma. We used varimax rotation to facilitate interpretation [10]. We assessed scale reliability using Cronbach’s α, for both the newly found scales and the original four scales. Subscales were constructed on the basis of the principal component analysis by adding the unweighted scores of the variables that loaded on a factor and normalizing to 0–100. Finally, we assessed construct validity as done in the earlier studies [4, 5], using correlations with the QLQ-CR30 (scores below 0.40 indicating no undue overlap between the constructs of the two questionnaires), and known-groups comparisons comparing older (≥66 years) and younger (≤65 years), patients with and without a stoma, and patients treated with curative and palliative intent using Mann–Whitney U tests.

Results

Characteristics of items

Table 2 presents the item characteristics and the subscales detected. ICCs were low for urinary incontinence and dysuria. The percentage respondents at floor was rather high (>50 %) in the blood and mucus in stool scale and for 19 individual items.
Table 2

Quality of life scores according the EORTC QLQ-CR29, structure and reliability

Scaling/single-item name n Item No.MeanSD α % floorc % ceilingc RangeICCsa
All patients 236
Urinary frequency31, 3232.224.00.7122.21.70–1000.33, 0.43
Blood and mucus in stool38, 397.915.90.5674.500–83.30.90, 0.72
Body image45–4718.521.70.8036.01.30–1000.76, 0.44, 0.41
Defaecation/stoma problems49–5421.419.10.849.600–88.9see below
Urinary incontinence337.618.282.30.90–1000.20
Dysuria344.113.790.20.40–1000.36
Abdominal pain3511.722.273.62.10–1000.79
Buttock pain3614.224.870.12.60–1000.74
Bloated feeling3716.022.761.11.30–1000.55
Dry mouth4018.625.758.92.50–1000.93
Hair loss418.320.983.32.10–1000.82
Trouble with taste4212.324.975.73.40–1000.75
Anxiety4333.826.426.34.20–1000.54
Weight4420.626.655.33.00–1000.71
Patients without stoma 168
(2) Flatulence4934.627.427.13.80–1000.64b
(2) Faecal incontinence5012.123.273.82.50–1000.75b
(2) Sore skin around anus5114.726.870.85.00–1000.82b
(2) Stool frequency52, 5324.122.60.6830.00.60–1000.81b, 0.27b
(2) Embarrassed by defaecation pattern5421.130.060.25.00–1000.65b
Defaecation problems49–5421.819.60.849.900–88.9
Patients with stoma 68
(2) Flatulence49s30.323.028.400–66.7See no stomab
(2) Faecal incontinence/leakage50s20.226.757.61.50–100
(2) Sore skin around stoma51s21.930.558.26.00–100
(2) Stool frequency/bags change52s, 53s14.420.40.7256.100–83.3
(2) Embarrassed by stoma54s20.927.155.23.00–100
(2) Stoma care problems55s8.619.781.800–66.7
Stoma problems49–54s20.417.90.809.000–77.8
Male 143
(1) Sexual functioning2630.625.431.12.20–1000.85b
(2) Impotence2741.741.742.326.00–1000.78b
Female 93
(1) Sexual functioning2816.122.861.21.20–100See malesb
(2) Dyspareunia2914.528.574.55.50–100

aIf two or more correlations are presented, these are in order of the items in column 3

bICCs are for patients with and without stoma (defaecation) and males and females (sex) combined

cPercentages scoring lowest (floor) and highest (ceiling) category

Quality of life scores according the EORTC QLQ-CR29, structure and reliability aIf two or more correlations are presented, these are in order of the items in column 3 bICCs are for patients with and without stoma (defaecation) and males and females (sex) combined cPercentages scoring lowest (floor) and highest (ceiling) category

Factor analysis and reliability

Factor analysis revealed seven factors, of which the original urinary frequency scale (Cronbach’s α = 0.71) and body image (α = 0.80) scales were reproduced (alpha in the original study [3] of 0.71 and 0.84, respectively). The original two-item stool frequency scale (items 52 and 53) had a lower α (0.68, originally 0.70 [3]) than when included in a larger factor, with all bowel and stoma problems included (items 49–54: α = 0.80). This latter scale also showed good reliability for patients with (α = 0.80) and without (α = 0.84) a stoma. The blood or mucus in stool scale was reproduced in the factor analysis but had a low α of 0.56 (originally 0.69 [3]). All remaining factors did not form clearly interpretable scales, and reliabilities were all below 0.70. We thus present construct validation for the original scales and items, as well as the new bowel/stoma problems scale.

Construct validity

Correlations between the subscales and the QLQ-C30 subscales were below 0.40, except for body image, which correlated moderately (r = 0.48) with social functioning. Younger compared to older patients had significantly worse sexual functioning (Table 3) and had fewer problems with urinary frequency and incontinence and with a dry mouth. Patients without a stoma had a higher body image and less urinary incontinence. Patients treated with curative intent indicated more problems with blood and mucus in stool, defaecation problems, buttock pain, and stool frequency and fewer problems with hair loss and trouble with taste than patients treated with palliative intent.
Table 3

Known-groups comparisons (age, stoma, treatment intent)

CR29AgeStomaTreatment curative intent
≤65≥66 p NoYes p YesNo p
Urinary frequency26.0 (21.4)38.1 (25.0).00***32.1 (24.6)32.3 (22.6).8932.5 (24.8)30.8 (20.2).85
Blood and mucus in stool9.2 (17.8)6.6 (13.9).339.3 (17.6)4.3(9.7).099.2 (17.0)1.3 (4.4).00***
Body image20.4 (23.2)16.7 (20.1).2414.0 (18.6)29.4 (24.6).00***18.6 (22.3)17.6 (18.4).70
Defaecation/stoma problems19.9 (18.7)22.8 (19.5).1921.8 (19.6)20.4 (17.9).7922.4 (19.0)16.9 (19.4).05*
Urinary incontinence4.7 (13.2)10.5 (21.7).03*5.8 (15.6)12.1 (23.1).02*7.6 (18.0)7.7 (19.4).77
Dysuria5.3 (15.7)3.3 (11.7).223.8 (13.4)5.1 (14.6).464.6 (14.2)1.7 (10.5).10
Abdominal pain11.7 (23.0)11.7 (21.4).8212.7 (23.3)9.0 (18.9).3211.8 (22.3)10.8 (21.9).80
Buttock pain14.2 (25.9)14.3 (23.9).7011.3 (22.7)21.7 (28.3).00***15.7 (25.4)7.5 (20.7).03*
Bloated feeling18.4 (24.7)13.9 (20.5).1817.2 (22.8)13.4 (22.5).1616.7 (23.3)13.3 (19.7).50
Dry mouth11.7 (19.8)25.1 (28.8).00***18.3 (25.7)19.6 (25.9).6817.7 (24.4)23.3 (31.3).41
Hair loss90.9 (22.4)92.5 (19.5).678.8 (21.7)7.1 (19.0).665.5 (15.1)23.9 (35.0).00**
Trouble with taste12.7 (24.5)12.0 (25.4).6612.0 (25.1)13.2 (24.5).4710.9 (24.5)19.2 (26.0).01*
Anxiety33.6 (27.9)33.9 (25.0).7935.5 (26.6)29.4 (25.5).1032.1 (24.9)41.7 (31.8).09
Weight18.1 (27.0)22.9 (26.2).0818.6 (26.0)25.5 (27.7).04*21.8 (26.8)14.5 (25.1).07
Without stoma
Flatulence32.1 (27.3)37.1 (27.6).2736.1 (26.5)7.6 (30.9).08
Faecal incontinence12.1 (23.3)12.1 (23.3)1.013.2 (23.3)6.9 (22.5).05*
Sore skin around anus16.1 (27.9)13.3 (25.8).4514.9 (27.1)13.8 (26.0).85
Stool frequency23.9 (23.3)24.3 (22.0).8225.7 (23.1)16.7 (18.4).05*
Embarrassed by defaecation pattern16.5 (26.4)25.8 (32.7).0822.5 (30.1)14.9 (29.0).15
With stoma
Flatulence28.7 (21.3)31.6 (24.4).6529.8 (23.5)33.3 (12.1).62
Faecal incontinence/leakage16.7 (24.8)22.8 (28.1).3621.8 (27.4)12.1 (22.5).26
Sore skin around stoma23.0 (32.2)21.1 (29.4).9123.2 (31.7)15.1 (22.9)54
Stool frequency/bags change11.5 (20.9)16.7 (20.0).1213.9 (20.2)1637 (22.3).59
Embarrassed by stoma14.9 (22.9)25.4 (29.4).1520.8 (26.6)21.2 (30.8).95
Stoma care problems6.0 (15.9)10.5 (22.1).449.1 (20.7)6.1 (13.5).90
Male
Sexual functioninga 37.6 (26.7)23.1 (22.0).00***31.1 (25.4)29.4 (25.7).6831.9 (25.4)22.8 (25.0).14
Impotence37.3 (42.1)47.0 (41.1).2133.3 (38.6)61.3 (42.7).00***40.9 (41.0)47.1 (47.2).71
Female
(1) Sexual functioninga 26.7 (26.4)6.7 (13.5).00***18.8 (24.6)8.7 (15.0).1016.4 (23.3)14.6 (21.0).86
(2) Dyspareunia21.0 (32.28.3 (23.4).069.2 (21.3)28.9 (39.6).0715.9 (30.9)9.1 (15.6).89

Higher scores indicate higher levels of symptoms or less functioning

* p ≤ .05; ** p ≤ .01; *** p ≤ .001 (Mann–Whitney U test)

aIn this area higher scores represent better functioning

Known-groups comparisons (age, stoma, treatment intent) Higher scores indicate higher levels of symptoms or less functioning * p ≤ .05; ** p ≤ .01; *** p ≤ .001 (Mann–Whitney U test) aIn this area higher scores represent better functioning

Discussion

This study largely replicates the findings of the original study [3] and the Spanish validation [5]. As in the original study, the body image and urinary frequency scales were reliable, while the blood and mucus scale was only moderately reliable. An important result is that we found a reliable scale incorporating the items about bowel problems or stoma problems. Neither the Spanish nor the Polish study performed an exploratory factor analysis and only reported the results for the scales defined in the original paper [3]. Since the original stool frequency scale was incorporated in this new scale, the questionnaire still consists of four scales, but with 14 additional single items instead of 19. For reasons of reliability and multiple testing, it is recommended to have as few single items as possible, so this is an improvement. Remarkable was the better item performance in our study compared to the Spanish validation, where ceiling effects were present in over 50 % of the scores in four domains (body image, anxiety, weight, and impotence). The patients in our sample scored markedly lower than those in the Spanish study, likely reflecting in part cultural values about body image and sexuality. Dysuria had similar high floor effects in the Spanish [5] and Danish [6] studies. We recommend additional assessment of the items urinary incontinence and dysuria, which showed poor reliability and item performance. Reliabilities of the items in the original study were higher than ours (ICCs > 0.55). The other studies did not report test–retest reliability. Construct validity was sufficient, as shown by only limited overlap between the QLQ-CR29 and QLQ-C30 (similar to the original study [3], apart from the correlation only we found between body image and social functioning). We also found differences in scores between groups that were well interpretable. We found fewer differences between patients with and without a stoma than the original study [3] (which also saw differences for the urinary frequency scale and the faecal incontinence, sore skin, and embarrassment items). Further, patients receiving palliative treatment in that study reported more problems with hair loss, anxiety, faecal incontinence, and dyspareunia, whereas in our study they reported less blood and mucus in stool and buttock pain, and lower stool frequency. In conclusion, we were able to replicate earlier findings, but could also reduce the number of single items and thus improve on the QLQ-CR29 as published so far. We recommend that the remaining individual items be revised to improve their performance, and that following that, more psychometric research be carried out to reduce the number of individual items.
  8 in total

1.  The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life.

Authors:  M A Sprangers; A te Velde; N K Aaronson
Journal:  Eur J Cancer       Date:  1999-02       Impact factor: 9.162

2.  Adaptation of quality of life module EORTC QLQ-CR29 for Polish patients with rectal cancer: initial assessment of validity and reliability.

Authors:  Wojciech Nowak; Beata Tobiasz-Adamczyk; Piotr Brzyski; Jerzy Sałówka; Dagmara Kuliś; Piotr Richter
Journal:  Pol Przegl Chir       Date:  2011-09

3.  The EORTC Quality of Life questionnaire for patients with colorectal cancer: EORTC QLQ-CR29 validation study for Spanish patients.

Authors:  Juan Ignacio Arraras; Javier Suárez; Fernando Arias de la Vega; Ruth Vera; Gemma Asín; Virginia Arrazubi; Mikel Rico; Lucía Teijeira; Jaione Azparren
Journal:  Clin Transl Oncol       Date:  2011-01       Impact factor: 3.405

4.  Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study.

Authors:  K C M J Peeters; C J H van de Velde; J W H Leer; H Martijn; J M C Junggeburt; E Klein Kranenbarg; W H Steup; T Wiggers; H J Rutten; C A M Marijnen
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

5.  Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer.

Authors:  R N Whistance; T Conroy; W Chie; A Costantini; O Sezer; M Koller; C D Johnson; S A Pilkington; J Arraras; E Ben-Josef; A M Pullyblank; P Fayers; J M Blazeby
Journal:  Eur J Cancer       Date:  2009-09-16       Impact factor: 9.162

Review 6.  Assessing quality of life in patients with colorectal cancer: an update of the EORTC quality of life questionnaire.

Authors:  S Gujral; T Conroy; C Fleissner; O Sezer; P M King; K N L Avery; P Sylvester; M Koller; M A G Sprangers; J M Blazeby
Journal:  Eur J Cancer       Date:  2007-05-22       Impact factor: 9.162

7.  Decision consultations on preoperative radiotherapy for rectal cancer: large variation in benefits and harms that are addressed.

Authors:  M Kunneman; C A M Marijnen; T Rozema; H M Ceha; D A R H Grootenboers; K J Neelis; A M Stiggelbout; A H Pieterse
Journal:  Br J Cancer       Date:  2014-10-21       Impact factor: 7.640

8.  Validation of the Danish version of the disease specific instrument EORTC QLQ-CR38 to assess health-related quality of life in patients with colorectal cancer.

Authors:  Henriette Vind Thaysen; P Jess; Søren Laurberg; M Groenvold
Journal:  Health Qual Life Outcomes       Date:  2012-12-14       Impact factor: 3.186

  8 in total
  17 in total

1.  Validation of the chinese version of the EORTC QLQ-CR29 in patients with colorectal cancer.

Authors:  Jin-Bo Lin; Lei Zhang; Dong-Wen Wu; Zhou-Huan Xi; Xue-Jun Wang; Yun-Shou Lin; Wakana Fujiwara; Jing-Ru Tian; Min Wang; Peng Peng; Ai Guo; Zhen Yang; Le Luo; Ling-Ya Jiang; Qia-Qia Li; Xue-Ying Zhang; Yun-Feng Zhang; Hou-Wei Xu; Bing Yang; Xun-Lin Li; Yi-Xiong Lei
Journal:  World J Gastroenterol       Date:  2017-03-14       Impact factor: 5.742

2.  Transanal minimally invasive surgery (TAMIS) versus endoscopic submucosal dissection (ESD) for resection of non-pedunculated rectal lesions (TRIASSIC study): study protocol of a European multicenter randomised controlled trial.

Authors:  Nik Dekkers; Jurjen J Boonstra; Leon M G Moons; Roel Hompes; Barbara A Bastiaansen; Jurriaan B Tuynman; Arjun D Koch; Bas L A M Weusten; Apollo Pronk; Peter A Neijenhuis; Marinke Westerterp; Wilbert B van den Hout; Alexandra M J Langers; Jolein van der Kraan; Alaa Alkhalaf; Jonathan Y L Lai; Frank Ter Borg; Hans Fabry; Eric Halet; Matthijs P Schwartz; Wouter B Nagengast; Jan Willem A Straathof; Rogier W R Ten Hove; Leendert H Oterdoom; Christiaan Hoff; Eric J Th Belt; David D E Zimmerman; Muhammed Hadithi; Hans Morreau; Erienne M V de Cuba; Jeroen W A Leijtens; Hans F A Vasen; Monique E van Leerdam; Eelco J R de Graaf; Pascal G Doornebosch; James C H Hardwick
Journal:  BMC Gastroenterol       Date:  2020-07-13       Impact factor: 3.067

3.  Translation and Validation of the Sinhala Version of the EORTC-QLQ-CR29 Questionnaire.

Authors:  Dakshitha P Wickramasinghe; Praveen Dayasena; Sanjeewa Seneviratne; Dharmabandhu N Samarasekera
Journal:  Asian Pac J Cancer Prev       Date:  2020-01-01

4.  Validation of Quality of Life Instruments for Cancer Patients - Colorectal Cancer (QLICP-CR) in patients with colorectal cancer in Northeast China.

Authors:  Min Liu; Wei Sun; Yuan-Yi Cai; Hua-Zhang Wu
Journal:  BMC Cancer       Date:  2018-12-07       Impact factor: 4.430

5.  Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

Authors:  Koen P Rovers; Checca Bakkers; Geert A A M Simkens; Jacobus W A Burger; Simon W Nienhuijs; Geert-Jan M Creemers; Anna M J Thijs; Alexandra R M Brandt-Kerkhof; Eva V E Madsen; Ninos Ayez; Nadine L de Boer; Esther van Meerten; Jurriaan B Tuynman; Miranda Kusters; Nina R Sluiter; Henk M W Verheul; Hans J van der Vliet; Marinus J Wiezer; Djamila Boerma; Emma C E Wassenaar; Maartje Los; Cornelis B Hunting; Arend G J Aalbers; Niels F M Kok; Koert F D Kuhlmann; Henk Boot; Myriam Chalabi; Schelto Kruijff; Lukas B Been; Robert J van Ginkel; Derk Jan A de Groot; Rudolf S N Fehrmann; Johannes H W de Wilt; Andreas J A Bremers; Philip R de Reuver; Sandra A Radema; Karin H Herbschleb; Wilhelmina M U van Grevenstein; Arjen J Witkamp; Miriam Koopman; Nadia Haj Mohammad; Eino B van Duyn; Walter J B Mastboom; Leonie J M Mekenkamp; Joost Nederend; Max J Lahaye; Petur Snaebjornsson; Cornelis Verhoef; Hanneke W M van Laarhoven; Aeilko H Zwinderman; Jeanette M Bouma; Onno Kranenburg; Iris van 't Erve; Remond J A Fijneman; Marcel G W Dijkgraaf; Patrick H J Hemmer; Cornelis J A Punt; Pieter J Tanis; Ignace H J T de Hingh
Journal:  BMC Cancer       Date:  2019-04-25       Impact factor: 4.430

6.  Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).

Authors:  Koen P Rovers; Robin J Lurvink; Emma Ce Wassenaar; Thomas Jm Kootstra; Harm J Scholten; Rudaba Tajzai; Maarten J Deenen; Joost Nederend; Max J Lahaye; Clément Jr Huysentruyt; Iris van 't Erve; Remond Ja Fijneman; Alexander Constantinides; Onno Kranenburg; Maartje Los; Anna Mj Thijs; Geert-Jan M Creemers; Jacobus Wa Burger; Marinus J Wiezer; Djamila Boerma; Simon W Nienhuijs; Ignace Hjt de Hingh
Journal:  BMJ Open       Date:  2019-07-27       Impact factor: 2.692

7.  Health-related quality of life in Slovenian patients with colorectal cancer: a single tertiary care center study.

Authors:  Jan Grosek; Jerica Novak; Katja Kitek; Alta Bajric; Ana Majdic; Jurij Ales Kosir; Ales Tomazic
Journal:  Radiol Oncol       Date:  2019-03-14       Impact factor: 2.991

8.  Effect of PRM1201 Combined With Adjuvant Chemotherapy on Preventing Recurrence and Metastasis of Stage III Colon Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  Ru Jia; Ningning Liu; Guoxiang Cai; Yun Zhang; Haijuan Xiao; Lihong Zhou; Qing Ji; Ling Zhao; Puhua Zeng; Huaimin Liu; Jiege Huo; Xiaoqiang Yue; Yi Zhang; Chaojun Wu; Xiaoting Sun; Yuanyuan Feng; Hongjie Liu; Hui Liu; Zhifen Han; Youying Lai; Yanbo Zhang; Gang Han; Hangjun Gong; Yan Wang; Qi Li
Journal:  Front Oncol       Date:  2021-03-03       Impact factor: 6.244

9.  First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II).

Authors:  Robin J Lurvink; Paulien Rauwerdink; Koen P Rovers; Emma C E Wassenaar; Maarten J Deenen; Joost Nederend; Clément J R Huysentruyt; Iris van 't Erve; Remond J A Fijneman; Erik J R J van der Hoeven; Cornelis A Seldenrijk; Alexander Constantinides; Onno Kranenburg; Maartje Los; Karin H Herbschleb; Anna M J Thijs; Geert-Jan M Creemers; Jacobus W A Burger; Marinus J Wiezer; Simon W Nienhuijs; Djamila Boerma; Ignace H J T de Hingh
Journal:  BMJ Open       Date:  2021-03-30       Impact factor: 2.692

10.  Validation of the Taiwan Chinese version of the EORTC QLQ-CR29 to assess quality of life in colorectal cancer patients.

Authors:  Ming-Hung Shen; Ling-Ping Chen; Thien-Fiew Ho; Ying-Yih Shih; Ching-Shui Huang; Wei-Chu Chie; Chi-Cheng Huang
Journal:  BMC Cancer       Date:  2018-04-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.